¡¶ÉÙÄêÅÉ¡·È«¼¯Ãâ·ÑÔÚÏßԢĿ-µçÊÓ¾ç-6080Ó°Ï·"/> ¡°¹²É̽ðÈÚ¿ª·ÅºÏ×÷£¬¹²Ïí¾¼ÃÎȹÌÉú³¤£¬³£É½½«Ò»Á¬×öºÃ¿Æ¼¼½ðÈÚ¡¢ÂÌÉ«½ðÈÚ¡¢ÆÕ»Ý½ðÈÚ¡¢ÑøÀϽðÈÚ¡¢Êý×Ö½ðÈÚÎåÆª´óÎÄÕ£¬ÌôÆð½ðÈÚÖ§³ÖµÄ´óÁº¡£¡±³£É½ÏØÎ¯Ïà¹ØÈÏÕæÈËÌåÏÖ¡£"/>
¡¶¡¶ÉÙÄêÅÉ¡·È«¼¯Ãâ·ÑÔÚÏßԢĿ-µçÊÓ¾ç-6080Ó°Ï·¡·¾çÇé¼ò½é£º¹²É̽ðÈÚ¿ª·ÅºÏ×÷¹²Ïí¾¼ÃÎȹÌÉú³¤³£É½½«Ò»Á¬×öºÃ¿Æ¼¼½ðÈÚ¡¢ÂÌÉ«½ðÈÚ¡¢ÆÕ»Ý½ðÈÚ¡¢ÑøÀϽðÈÚ¡¢Êý×Ö½ðÈÚÎåÆª´óÎÄÕÂÌôÆð½ðÈÚÖ§³ÖµÄ´óÁº³£É½ÏØÎ¯Ïà¹ØÈÏÕæÈËÌåÏÖ;¡¶ÉÙÄêÅÉ¡·È«¼¯Ãâ·ÑÔÚÏßԢĿ-µçÊÓ¾ç-6080ӰϷǬÀ¤Ö®Ö÷ÄÇÏÖÔÚÔõô°ìÕâÁ½ÈË»ù´¡¾Í²»¿É¹»±»×¥²¶Õ½Ê¤ËҲûÓÐÏëµ½ÄÇ·½º®¾ÓÈ»ÐÞÁ¶µÖ´ïÁËÕâÑùµÄ¾³½çÒ»µÀÒõÑôÖ®Æø³åÏ´Á˳öÀ´Äý¾Û³ÉÁËÒõÑôÖ®Ö÷ËûÉñÉ«²Ò°×ÊÜÉ˺ÜÖØ²¢ÇÒ»¹ËðʧÁËѹÏäµ×µÄÊÖ¶ÎÒõÑô·¨Éñƾ֤¹ú¼ÊºìÊ®×Ö»áµÄ½¨Ò鵨¶¯±¬·¢ºóÖ»¹Ü×èֹʹÓõçÌÝÒÔÃâÔÚÕð¾ªÖб»À§ÕÆÎÕÕâЩ¼òÆÓµÄ×Ô¾ÈÒªÁì²»µ«ÄÜÔÚÒªº¦Ê±¿Ì±£»¤ÉúÃüÒ²ÌåÏÖÁËСÎÒ˽¼Ò¶ÔÉúÑĵÄÖØÊÓÓë¶Ô¼ÒÍ¥µÄÔðÈÎ
¡¶¡¶ÉÙÄêÅÉ¡·È«¼¯Ãâ·ÑÔÚÏßԢĿ-µçÊÓ¾ç-6080Ó°Ï·¡·ÊÓÆµËµÃ÷£ºÕ¶Âó̳¤µÄÈËÕ¾ºÍ×øÕæµÄ²îÌØÊâ¶àÕ¾Ò»Æð»¹Ã»ÉϰྫÉñ¶¼Òª±ÀÁË2024-10-15 12:18¡¤Ð¡ÍæÒâ¶ù
ÎÞÛóµÄ²Ôñ·ºÆµ´µÄÒâ3. Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, et al.. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: a systematic review. Medicine. 2020 Jan;99(5):e19013.
27¡¢ÇຣºþС»·Ïߣ¨Çຣºþ¡ª²è¿¨Ñκþ£©
2025-10-03 08:52:20